Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
3.650
+0.130 (3.69%)
Mar 31, 2025, 1:27 PM EDT - Market open
Foghorn Therapeutics Employees
Foghorn Therapeutics had 112 employees as of December 31, 2024. The number of employees decreased by 4 or -3.45% compared to the previous year.
Employees
112
Change (1Y)
-4
Growth (1Y)
-3.45%
Revenue / Employee
$201,804
Profits / Employee
-$773,393
Market Cap
202.98M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 112 | -4 | -3.45% |
Dec 31, 2023 | 116 | -45 | -27.95% |
Dec 31, 2022 | 161 | 42 | 35.29% |
Dec 31, 2021 | 119 | 24 | 25.26% |
Dec 31, 2020 | 95 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
FHTX News
- 5 days ago - Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting - GlobeNewsWire
- 24 days ago - Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook - GlobeNewsWire
- 4 weeks ago - Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities - GlobeNewsWire
- 4 months ago - Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update - GlobeNewsWire
- 6 months ago - Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors - GlobeNewsWire
- 6 months ago - Foghorn Therapeutics to Participate in the BMO Oncology Summit - GlobeNewsWire